{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T02:07:50Z","timestamp":1769479670063,"version":"3.49.0"},"reference-count":117,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>B7-H3 (CD276), a member of the B7 family of proteins, is known to play a key role in the progression of a number of cancers. This protein is selectively expressed in both tumor cells and immune cells within the tumor microenvironment. Various investigations, including a number of clinical trials, have reported high levels of expression of this protein in cancerous tissues compared to their healthy counterparts. This difference in expression attracted various research efforts to establish whether such a difference can be linked to the therapeutic potential of this molecule. It is worth noting that B7-H3 is not the only immune checkpoint expressed at different levels in cancerous and healthy cells. Therapeutic strategies, based on different levels of expression, have been tested with other checkpoints. To inhibit the expression of some checkpoints, immune checkpoint inhibitors (ICIs) were developed. The introduction of these inhibitors for the treatment of some forms of advanced-stage tumors has been justly described as an important milestone in the landscape of immune therapy. Years after the launch of these inhibitors, numerous clinical trials revealed that these inhibitors benefit a narrow subset of patients suffering from advanced-stage tumors, while the majority of patients treated with these inhibitors either did not respond positively or simply did not respond at all (refractory patients). Other clinical trials showed that this form of treatment can provoke serious immune-related adverse events (irAEs). It is fair to state that changes in the expression level of a given protein in diseased tissue is an important parameter to take into account in the assessment of such a protein as a therapeutic target. However, the last ten years have demonstrated that taking the level of expression of a given checkpoint within a cancerous tissue is not sufficient to consider such expression a reliable predictive biomarker for the investigated disease. On the other hand, to establish a solid base for a given therapeutic strategy, these varying levels of expression have to be combined with a deep understanding of the biology of the molecule under investigation, as well as the identification and thorough analysis of the relevant signaling pathways, particularly those communicating with both the investigated molecule and the immune system. Recently, a number of pharmaceutical and biotechnology firms have suggested that B7-H3 is a highly promising therapeutic target for the development of immune therapeutics. In this review, we ask why hopes of better therapeutic performance are attached to this immune checkpoint. A partial answer to this question is provided through the careful consideration of the available data generated by various clinical trials. The contribution of mass spectrometry-based proteomics to this area of research is highlighted.<\/jats:p>","DOI":"10.3390\/cells15030239","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T15:48:30Z","timestamp":1769442510000},"page":"239","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does the B7-H3 Immune Checkpoint Have High Potential as a Therapeutic Target?"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-1233","authenticated-orcid":false,"given":"Marco","family":"Agostini","sequence":"first","affiliation":[{"name":"Istituto di Ricerca Pediatrica Citt\u00e0 della Speranza, Corso Stati Uniti 4, 35100 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-3614","authenticated-orcid":false,"given":"Pietro","family":"Traldi","sequence":"additional","affiliation":[{"name":"Istituto di Ricerca Pediatrica Citt\u00e0 della Speranza, Corso Stati Uniti 4, 35100 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Hamdan","sequence":"additional","affiliation":[{"name":"Istituto di Ricerca Pediatrica Citt\u00e0 della Speranza, Corso Stati Uniti 4, 35100 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/curroncol29010004","article-title":"New strategies and combinations to improve outcomes in immunotherapy in metastatic non-small-cell lung cancer","volume":"29","author":"Corke","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1017\/S0266462325100317","article-title":"Predicting response to immunotherapy in lung cancer: An early HTA of predictive tests","volume":"41","author":"Govers","year":"2025","journal-title":"J. Technol. Assess. Health Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1003196","DOI":"10.37349\/ei.2025.1003196","article-title":"Immune-checkpoint inhibitor resistance in patients with cancer","volume":"5","year":"2025","journal-title":"Explor. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Serrat\u00ec, S., and Margheri, F. (2023). Current Landscape and Future Direction of PD-1\/PD-L1 Checkpoint Inhibitors in Cancer Treatment. Biomolecules, 13.","DOI":"10.3390\/biom13081209"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2326-6066.CIR-20-0586","article-title":"Hallmarks of Resistance to Immune-Checkpoint Inhibitors","volume":"10","author":"Karasarides","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Nardin, S., Ruffilli, B., Costantini, P., Rocco Mollace, R., Ida Taglialatela, I., Pagnesi, M., Chiarito, M., Soldato, D., Cao, D., and Conte, B. (2025). Navigating Cardiotoxicity in Immune Checkpoint Inhibitors: From Diagnosis to Long-Term Management. J. Cardiovasc. Dev. Dis., 12.","DOI":"10.3390\/jcdd12070270"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Agostini, M., Traldi, P., and Hamdan, M. (2025). The Search for Predictive Biomarkers in Response to Immune Checkpoint Inhibitors and Associated Adverse Events. J. Pers. Med., 15.","DOI":"10.3390\/jpm15120596"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tao, W., Sun, Q., Xu, B., and Wang, R. (2025). Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review. Life, 15.","DOI":"10.3390\/life15020283"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"216182","DOI":"10.1016\/j.canlet.2023.216182","article-title":"Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions","volume":"562","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: Role of ATP\u2013dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Elbahnsi, A., Dudas, B., Callebaut, I., Hinzpeter, A., and Miteva, M.A. (2024). ATP-Binding Cassette and Solute Carrier Transporters: Understanding Their Mechanisms and Drug Modulation Through Structural and Modeling Approaches. Pharmaceuticals, 17.","DOI":"10.3390\/ph17121602"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100478","DOI":"10.1016\/j.ejcped.2025.100478","article-title":"P-glycoprotein as a chemotherapy resistance mechanism and biomarker of poor response in high-risk neuroblastoma","volume":"6","author":"Atkinson","year":"2025","journal-title":"EJC Paediatr. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez-Carrasco, P., Morales-Villamil, F., and Maldonado-Bernal, C. (2025). P-Glycoprotein as a Therapeutic Target in Hematological Malignancies: A Challenge to Overcome. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104701"},{"key":"ref_14","first-page":"405","article-title":"Generating Inhibitors of P-Glycoprotein: Where to, now? Multi-Drug Resist","volume":"596","author":"Crowley","year":"2010","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Agostini, M., Traldi, P., and Hamdan, M. (2024). Mass Spectrometry Investigation of Some ATP-Binding Cassette (ABC) Proteins. Medicina, 60.","DOI":"10.3390\/medicina60020200"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"48507","DOI":"10.18632\/oncotarget.17397","article-title":"Implementing liquid biopsies into clinical decision making for cancer immunotherapy","volume":"8","author":"Quandt","year":"2017","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2024.11.009","article-title":"Advances in liquid biopsy: From exploration to practical application","volume":"43","author":"Pantel","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/s41592-024-02541-x","article-title":"A new understanding of tissue biology from MS-based proteomics at single-cell resolution","volume":"21","author":"Nordmann","year":"2024","journal-title":"Nat. Methods"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12014-023-09424-x","article-title":"Mass spectrometry-based proteomics as an emerging tool in clinical laboratories","volume":"20","author":"Birhanu","year":"2023","journal-title":"Clin. Proteom."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41586-025-08584-0","article-title":"Mass-spectrometry-based proteomics: From single cells to clinical applications","volume":"638","author":"Guo","year":"2025","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-021-00418-2","article-title":"Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation","volume":"11","author":"Derman","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood.2024024041","article-title":"Mass spectrometry\u2013based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma","volume":"144","author":"Kubicki","year":"2024","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1158\/1535-7163.MCT-21-0554","article-title":"DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models","volume":"21","author":"Yamato","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1177\/1535370219855970","article-title":"Considering B7-CD28 as a family through sequence and structure","volume":"244","author":"West","year":"2019","journal-title":"Exp. Biol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ahangar, N.K., Hemmat, N., Khalaj-Kondori, M., Shadbad, M.A., Sabaie, H., Mokhtarzadeh, A., Alizadeh, N., Derakhshani, A., Baghbanzadeh, A., and Dolatkhah, K. (2021). The regulatory cross-talk between microRNAs and novel members of the B7 family in human diseases: A scoping review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052652"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Shadbad, M.A., Safaei, S., Brunetti, O., Derakhshani, A., Lotfinejad, P., Mokhtarzadeh, A., Hemmat, N., Racanelli, V., Solimando, A.G., and Argentiero, A. (2021). A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: To-ward Single-Cell Sequencing-Guided Biomimetic Delivery. Genes, 12.","DOI":"10.3390\/genes12081206"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/bjc.2014.113","article-title":"Identifying microRNAs regulating B7-H3 in breast cancer: The clinical impact of microRNA-29c","volume":"110","author":"Nygren","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41419-024-06791-7","article-title":"The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma","volume":"15","author":"Pathania","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zhao, S., Zhang, H., and Shang, G. (2025). Research progress of B7-H3 in malignant tumors. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1586759"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41467-021-22618-x","article-title":"FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1038\/s41467-025-58740-3","article-title":"Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity","volume":"16","author":"Huang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.tips.2025.08.008","article-title":"The B7-H3 (CD276) pathway: Emerging biology and clinical therapeutics","volume":"46","author":"Corrigan","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wang, L., Yang, Z., Guo, F., Chen, Y., Wei, J., Dai, X., and Zhang, X. (2023). Research progress of biomarkers in the prediction of anti-PD-1\/PD-L1 immunotherapeutic efficiency in lung cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1227797"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nchembio.2194","article-title":"Oligosaccharyltransferase Inhibition Induces Senescence in RTK-Driven Tumor Cells","volume":"12","author":"Shrima","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/s41556-024-01500-0","article-title":"A size filter at the Golgi regulates apical membrane protein sorting","volume":"26","author":"Macara","year":"2024","journal-title":"Nat. Cell Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/s41388-023-02622-9","article-title":"Glucose-mediated N-glycosylation of RPTP alpha affects its subcellular localization and Src activation","volume":"42","author":"Fang","year":"2023","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: Mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1038\/s41467-020-19052-w","article-title":"A streamlined pipeline for multiplexed quantitative site-specific N-glycoproteomics","volume":"11","author":"Fang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1007\/s11010-025-05303-1","article-title":"Glycosylation in cancer: Mechanisms, diagnostic markers, and therapeutic application","volume":"480","author":"Qusairy","year":"2025","journal-title":"Mol. Cell. Biochem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/tbj.13696","article-title":"Triple-negative breast cancer\u2014Role of immunology: A systemic review","volume":"26","author":"Oner","year":"2020","journal-title":"Breast J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10549-009-0674-9","article-title":"An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients","volume":"123","author":"Lanczky","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10549-011-1457-7","article-title":"bc-GenExMiner: An easy-to-use online platform for gene prognostic analyses in breast cancer","volume":"131","author":"Campone","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41392-025-02219-6","article-title":"N-deglycosylation targeting chimera (DGlyTAC): A strategy for immune checkpoint proteins inactivation by specifically removing N-glycan","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1\/PD-L1 Therapeutic Efficacy","volume":"36","author":"Lee","year":"2019","journal-title":"Cancer Cell."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Jukovi\u0107-Bihorac, F., \u0110uri\u010di\u0107, S., Begagi\u0107, E., Be\u010duli\u0107, H., Efendi\u0107, A., Vrani\u0107, S., and Mirza Pojski\u0107, M. (2025). B7-H3 as a Reliable Diagnostic Biomarker for the Differentiation of High-Grade Gliomas (HGGs) and Low-Grade Gliomas (LGGs). Brain Sci., 15.","DOI":"10.3390\/brainsci15080872"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"15330338251380957","DOI":"10.1177\/15330338251380957","article-title":"B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy","volume":"24","author":"Zhang","year":"2025","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1038\/s41379-020-0587-z","article-title":"B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma","volume":"33","author":"Lu","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s00262-021-02862-2","article-title":"miR-34a induces immunosuppression in colorectal carcinoma through modulating a SIRT1\/NF-\u03baB\/B7-H3\/TNF-\u03b1 axis","volume":"70","author":"Meng","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Joshi, V., Beecher, K., Lim, M., Stacey, A., Feng, Y., Jat, P.S., Duijf, P.H.G., Simpson, P.T., Lakhani, S.R., and Reed, A.E.M. (2024). B7-H3 expression in breast cancer and brain metastasis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073976"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"101874","DOI":"10.1016\/j.tranon.2023.101874","article-title":"High expression of B7-H3 on monocyte\/macrophages in tumor microenvironment promotes lung cancer progression by inhibiting apoptosis","volume":"41","author":"Zhang","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.2147\/OTT.S169811","article-title":"B7-H3 promotes metastasis, proliferation, and epithelial-mesenchymal transition in lung adenocarcinoma","volume":"11","author":"Yu","year":"2018","journal-title":"OncoTargets Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1097\/CM9.0000000000002772","article-title":"B7-H3 confers stemness characteristics to gastric cancer cells by promoting glutathione metabolism through AKT\/pAKT\/Nrf2 pathway","volume":"136","author":"Xia","year":"2023","journal-title":"Chin. Med. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"108753","DOI":"10.1016\/j.clim.2021.108753","article-title":"Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer","volume":"227","author":"Li","year":"2021","journal-title":"Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1182\/blood.2021014671","article-title":"Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML","volume":"139","author":"Tyagi","year":"2022","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41408-024-01050-6","article-title":"Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody","volume":"14","author":"Hagelstein","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40478-021-01167-w","article-title":"The expression of B7-H3 isoforms in newly diagnosed glioblastoma and recurrence and their functional role","volume":"9","author":"Digregorio","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Y\u00fcceer, R.O., Kaya, S., Balc\u0131, S.N., E\u011filmez, H.R., Y\u0131lmaz, M., and Erd\u0131s, E. (2025). Prognostic biomarkers in isocitrate dehydrogenase wild-type glioblastoma: A focus on B7-H3. Brain Sci., 15.","DOI":"10.3390\/brainsci15020212"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/85339","article-title":"B7-H3: A costimulatory molecule for T cell activation and IFN-\u03b3 production","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","article-title":"Immune checkpoint of B7-H3 in cancer: From immunology to clinical immunotherapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1200\/JCO.20.01974","article-title":"B7H3-directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: Results of a phase I study","volume":"38","author":"Modak","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"53","DOI":"10.36401\/JIPO-23-18","article-title":"B7-H3 Inhibitors in Oncology Clinical Trials: A Review","volume":"7","author":"Feustel","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Malapelle, U., Parente, P., Pepe, F., Di Micco, M.C., Russo, A., Clemente, C., Graziano, P., and Rossi, A. (2022). B7-H3\/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232416077"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaad.2024.08.036","article-title":"Dermatologic toxicities of antibody-drug conjugates","volume":"91","author":"Gronbeck","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"He, J., Zeng, X., Wang, C., Wang, E., and Li, Y. (2024). Antibody\u2013drug conjugates in cancer therapy: Mechanisms and clinical studies. MedComm, 5.","DOI":"10.1002\/mco2.671"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: A phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1016\/j.jtho.2023.09.667","article-title":"P2.16-06 A Phase 2 Study of Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Previously Treated ES-SCLC","volume":"18","author":"Rudin","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jtho.2024.09.033","article-title":"OA04.03 Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Interim Analysis of Ideate-lung01","volume":"19","author":"Rudin","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3892\/mco.2023.2643","article-title":"Development, efficacy and side effects of antibody-drug conjugates for cancer therapy (Review)","volume":"18","author":"Sun","year":"2023","journal-title":"Mol. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_73","first-page":"728","article-title":"AJICAP second generation: Improved chemical site-specific conjugation technology for antibody-drug conjugate production","volume":"34","author":"Fujii","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0140-6736(22)02534-X","article-title":"second-generation antibody-drug conjugate to treat HER2-positive breast cancer","volume":"401","author":"Rassy","year":"2023","journal-title":"Lancet"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12272-023-01479-6","article-title":"Antibody-drug conjugates in cancer therapy: Innovations, challenges, and future directions","volume":"47","author":"Kumari","year":"2024","journal-title":"Arch Pharm Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e70001","DOI":"10.1111\/eci.70001","article-title":"Adverse events and impact on quality of life of antibody drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta-analysis","volume":"55","author":"Perachino","year":"2025","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.annemergmed.2024.10.015","article-title":"Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know","volume":"85","author":"Markides","year":"2025","journal-title":"Ann. Emerg. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.2024024442","article-title":"Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms","volume":"144","author":"Taylor","year":"2024","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14740338.2023.2204228","article-title":"High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive\/mutated malignancies: A pharmacovigilance study based on the FAERS database","volume":"22","author":"Pan","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11596-025-00030-6","article-title":"Toxicities Associated with Sacituzumab Govitecan: Data from Clinical Trials and a Real-World Pharmacovigilance Database","volume":"45","author":"Tan","year":"2025","journal-title":"Curr. Med. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101155","DOI":"10.1016\/j.gore.2023.101155","article-title":"Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine","volume":"47","author":"Hendershot","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"139","DOI":"10.6004\/jadpro.2023.14.2.4","article-title":"Tisotumab Vedotin Safety and Tolerability in Clinical Practice: Managing Adverse Events","volume":"14","author":"Arn","year":"2023","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"102574","DOI":"10.1016\/j.canep.2024.102574","article-title":"Side effects of drug-antibody conjugates enfortumab-vedotin and sacituzumab-govitecan in targeted therapy in cancer","volume":"90","author":"Reike","year":"2024","journal-title":"Cancer Epidemiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2165\/00003495-200161090-00007","article-title":"Gemtuzumab ozogamicin","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/mabs.20230","article-title":"Brentuximab vedotin","volume":"4","author":"Dhimolea","year":"2012","journal-title":"MAbs"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00280-011-1817-3","article-title":"Clinicalpharmacology of trastuzumab emtansine (T-DM1): An antibody\u2013drug conjugate in development for the treat-ment of HER2-positive cancer","volume":"69","author":"Girish","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.3240341","article-title":"Calicheamicin \u03b3 1 I: An Antitumor Antibiotic That Cleaves Double-Stranded DNA Site Specifically","volume":"240","author":"Zein","year":"1988","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.breast.2022.10.016","article-title":"Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer","volume":"66","author":"Rassy","year":"2022","journal-title":"Breast"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study ofanti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"mAbs"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"20406207221087511","DOI":"10.1177\/20406207221087511","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: A review of clinical data","volume":"13","author":"Furqan","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab Vedotin: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Mielcarska, S., Kot, A., Dawidowicz, M., Kula, A., Sobk\u00f3w, P., K\u0142aczka, D., Waniczek, D., and \u015awi\u0119tochowska, E. (2025). B7-H3 in Cancer Immunotherapy\u2014Prospects and Challenges: A Review of the Literature. Cells, 14.","DOI":"10.3390\/cells14151209"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/0008-5472.CAN-22-2155","article-title":"RNA therapeutics for improving CAR T cell safety and efficacy","volume":"83","author":"Schaible","year":"2023","journal-title":"Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Khan, A.N., Chowdhury, A., Karulkar, A., Jaiswal, A.K., Banik, A., Asija, S., and Purwar, R. (2022). Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.886546"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-L\u00f3pez, A., Olaya-Vargas, A., Bustamante-Ogando, J.C., and Meneses-Acosta, A. (2025). Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases. Pharmaceuticals, 18.","DOI":"10.3390\/ph18020156"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","article-title":"Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety","volume":"154","author":"Ellerman","year":"2019","journal-title":"Methods"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"102117","DOI":"10.1016\/j.xcrm.2025.102117","article-title":"Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses","volume":"6","author":"Lin","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"111605","DOI":"10.1016\/j.biopha.2021.111605","article-title":"CAR-macrophage: A new immuno-therapy candidate against solid tumors","volume":"139","author":"Chen","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","article-title":"New immune cell engagers for cancer immuno-therapy","volume":"24","author":"Fenis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","article-title":"Designing Cancer Immunotherapies That Engage T Cells and NK Cells","volume":"41","author":"Kyrysyuk","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Wucherpfennig, K.W., Gagnon, E., Call, M.J., Huseby, E.S., and Call, M.E. (2010). Structural biology of the T-cell receptor: Insights into receptor assembly, ligand recognition, and initiation of signaling. Cold Spring Harb. Perspect. Biol., 2.","DOI":"10.1101\/cshperspect.a005140"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_110","first-page":"865","article-title":"Second cancers after medulloblastoma: Population-based results from the United States and Sweden","volume":"8","author":"Goldstein","year":"1997","journal-title":"Cancer Causes Control."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.phoj.2023.05.001","article-title":"Review of the impact of molecular analysis on the therapy of medulloblastoma","volume":"8","author":"Sarvode","year":"2023","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Zareei, S., Khorsand, B., Dantism, A., Zareei, N., Asgharzadeh, F., Zahraee, S.S., Kashan, S.M., Hekmatirad, S., Amini, S., and Ghasemi, F. (2024). PeptiHub: A curated repository of precisely annotated cancer-related peptides with advanced utilities for peptide exploration and discovery. Database, 2024.","DOI":"10.1093\/database\/baae092"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12020-024-03911-3","article-title":"A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma","volume":"86","author":"Haghzad","year":"2024","journal-title":"Endocrine"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.tips.2017.09.002","article-title":"Challenges and Recent Advances in Medullo-blastoma Therapy","volume":"38","author":"Kumar","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/JMDH.S167808","article-title":"Medulloblastoma: Optimizing care with a multidisciplinary approach","volume":"12","author":"Thomas","year":"2019","journal-title":"J. Multidiscip. Healthc."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.stem.2021.04.011","article-title":"CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance","volume":"28","author":"Wang","year":"2021","journal-title":"Cell Stem Cell."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10555-025-10294-y","article-title":"B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors","volume":"44","author":"Jansen","year":"2025","journal-title":"Cancer Metastasis Rev."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/3\/239\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T15:59:50Z","timestamp":1769443190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/3\/239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":117,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cells15030239"],"URL":"https:\/\/doi.org\/10.3390\/cells15030239","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]}}}